Severe immune checkpoint inhibitor-associated gastritis: A case series and literature review

Authors
Yuya Sugiyama1, Hiroki Tanabe1, Taisuke Matsuya2, Yu Kobayashi1, Yuki Murakami1, Takahiro Sasaki1, Takehito Kunogi1, Keitaro Takahashi1, Katsuhiro Ando1, Nobuhiro Ueno1, Shin Kashima1, Kentaro Moriichi1, Mishie Tanino1, Yusuke Mizukami1, Mikihiro Fujiya1, Toshikatsu Okumura1

Institutions
1 Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Hokkaido, Japan
2 Department of Dermatology, Asahikawa Medical University, Asahikawa, Hokkaido, Japan
3 Department of Diagnostic Pathology, Asahikawa Medical University Hospital, Asahikawa Medical University, Asahikawa, Hokkaido, Japan

submitted 5.1.2022
accepted after revision 28.4.2022
published online 28.4.2022

Bibliography
Endosc Int Open 2022; 10: E982–E989
DOI 10.1055/a-1839-4303
ISSN 2364-3722
© 2022. The Author(s).

Background and study aims Recent advances in cancer treatment have involved the clinical application of immune checkpoint inhibitors (ICIs) for various type of cancers. The adverse events associated with ICIs are generally referred to as immune-related adverse events (irAEs). Gastrointestinal irAEs are a major disorder, but gastritis is not frequently observed. The aims of this study were to elucidate the clinical, endoscopic, and histological characteristics of irAE gastritis.

Patients and methods Information on patients treated with ICIs were collected from a single institute over 3 years. IrAE gastritis was identified based on the clinical course and endoscopic and histopathological findings. Of the 359 patients treated with ICIs, four cases of irAE gastritis were identified in clinical records from the endoscopy unit. The endoscopic and histopathological findings were analyzed, and further immunohistochemical studies with immune subtype markers and programmed cell death ligand-1 (PD-L1) antibody were conducted.

Results Among four patients with irAE gastritis, the remarkable endoscopic characteristics were network-pattern erosion, erythematous and edematous mucosa with thick purulent discharge, and fragile mucosa. Corresponding histological features were fibrinopurulent exudate, severe inflammatory cell infiltration, and epithalaxia, respectively. The PD-L1 expression rate was ≥1 % in the gastric tissue of all patients with gastritis. These patients were treated with prednisolone (PSL) and their symptoms improved within a few days to 2 weeks.

Conclusions IrAE gastritis were characterized by specific endoscopic findings. The appropriate endoscopic diagnosis may lead to effective treatment with PSL.
Introduction

Immune checkpoint inhibitors (ICIs) represent a major advance in treatment of many types of cancers and have dramatically changed the cancer therapeutic strategy. The efficacy of ICI treatment has been confirmed, and real-world clinical experience with its application has been gained. However, a wide spectrum of accompanying immune-related adverse events (ir-AEs) have been reported, with caution advised by expert oncologists [1]. These ir-AEs are driven by the immunologic mechanisms responsible for the therapeutic effects of ICIs [2, 3].

Gastrointestinal disorders are particularly common ir-AEs, and most patients develop severe inflammation in the colon [4, 5]. IrAE gastritis was first reported in 2017 [6], with more case reports on gastritis published later [7–14]. All reports described the severity and rarity of this gastritis. However, details concerning the clinical features of irAE gastritis remain sparse.

Symptoms in patients with irAE gastritis are non-specific. An accurate diagnosis should be made, based on a combination of a patient's clinical course and endoscopic and histopathological findings [13, 14]. Therefore, we retrospectively collected cases and reviewed the relevant literature to assess the characteristics of irAE gastritis, focusing on endoscopic findings and results of histopathological analyses.

Patients and methods

We conducted an observational retrospective study to collect information on patients with irAE gastritis. Three hundred and fifty-nine patients were treated with ICIs in Asahikawa Medical University Hospital from October 2018 to October 2021. Among them, 10 patients underwent esophagogastroduodenoscopy (EGD) due to complaints of gastrointestinal symptoms after administration of an ICI. Severe gastritis was observed in four patients. IrAE gastritis was identified based on the clinical course and endoscopic and histopathological findings. Detailed information was collected about the patients with irAE gastritis, including their symptoms, current treatments, and later immune therapy. The diagnostic criteria for irAE gastritis were onset of upper gastrointestinal symptoms while a patient was receiving ICIs, and the exclusion of other causes endoscopically and/or histologically.

Endoscopic findings were evaluated with conventional endoscopy, chromoendoscopy, and narrow-band imaging using gastroduodenoscopy (GIF-H290Z, GIF-HQ290 or GIF-1200N, Olympus Optical Co., Ltd., Tokyo, Japan). Biopsy specimens were collected from the antrum and corpus of the stomach for histological diagnosis in patients suspected of having irAE.

Immunohistochemical analyses were further conducted for patients with irAE gastritis. Immune subtype markers, including CD4 (1F6; Leica Microsystems, Wetzlar, Germany) and CD8 (C8/144B; Agilent Technology, Santa Cruz, CA, USA), and programmed cell death ligand-1 (PD-L1) antibody (SP263; Ventana Medical Systems, Tucson, AZ, USA) were used for immunohistochemistry. Expression of PD-L1 was evaluated as the positive rate (%) in total cells including epithelial cells and infiltrating lymphocytes.

| Case | Age | Sex | Cancer type | ICI history | ICI modification | Time to onset of symptoms (weeks) | Time to improvement of symptoms | Prednisolone treatment | ICI rechallenge | Relapse of gastritis | Nausea/vomiting | Loss of appetite | Other | Symptoms | CTCAE grade |
|------|-----|-----|-------------|-------------|-----------------|-------------------------------|-------------------------------|-------------------------|-------------------|-------------------|----------------|----------------|--------|----------|------------|
| 1    | 84  | M   | Melanoma    | Pembrolizumab | Nivolumab     | 1                            | +                            | 3                       | 2                 | A few days         | Div (0.5 mg/kg) | -               | Fatigue | Heartburn | 3          |
| 2    | 75  | F   | Melanoma    | Pembrolizumab | Nivolumab     | 40                           | +                            | 3                       | 2                 | A few days         | Div (0.5 mg/kg) | -               | -       | -         | 2          |
| 3    | 65  | M   | Lung cancer | Pembrolizumab | Nivolumab     | 15                           | +                            | 3                       | 2                 | A few days         | Div (0.5 mg/kg) | -               | -       | -         | 2          |
| 4    | 62  | M   | Gastric cancer | - | Nivolumab | 24                           | +                            | -                        | -                 | 1                 | -               | -               | -       | -         | 1          |

ICIs: immune checkpoint inhibitors; CTCAE: Common Terminology Criteria for Adverse Events

Table 1. Characteristics of patients with immune-related gastritis.
immunocytes. Cytomegalovirus (CMV) antibody (DDG9 + C C H 2 , D A K O g i l e n t , C a r p i n t e r i a, California, United States) was used for CMV immunohistochemistry. Warthin-Starry staining was performed to investigate Helicobacter pylori infection.

This observational study protocol was approved by the Asahikawa Medical University Research Ethics Committee (No. 210769). A written informed consent was obtained from each patient with irAE gastritis.

Results

Patient characteristics

Ten patients underwent EGD due to complaints of gastrointestinal symptoms after the administration of an ICI. Severe gastritis was observed in four of 359 patients (1.1%). These adverse events (AEs) were graded >2 because all patients were treated with prednisolone (PSL). Three patients were admitted to the hospital, and the incidence of grade 3 irAE gastritis was found to be 0.84% (3/359).

All four of these patients were finally diagnosed with irAE gastritis, and their clinical information is shown in Table 1. These four patients were two males and two females, with a median age of 70 years (range 62–84), treated with ICIs due to malignant melanoma (n = 2), lung cancer (n = 1), and gastric cancer (n = 1). Pembrolizumab had been administered to the melanoma patient and the lung cancer patient, nivolumab to the gastric cancer patient, and nivolumab/ipilimumab to the melanoma patient. Symptoms of irAE gastritis occurred 1 to 40 weeks after administration of ICIs. Among the affected patients, two patients had a history of ICI treatment and they did not develop irAE during the treatment. Common gastrointestinal symptoms, such as nausea, vomiting, and loss of appetite, occurred in all patients, and fatigue and heartburn were observed in one patient.

Endoscopic and histopathological findings at the diagnosis

Endoscopic and histopathological findings from patients with irAE gastritis are shown in Table 2. EGD revealed various findings, such as network-pattern erosion or ulceration in the antrum (Fig. 1a), erythematous and edematous mucosa with whitish purulent discharge (Fig. 1b), and fragile mucosa (Fig. 1c). The whitish discharge was remarkably increased by

| Case | Endoscopic findings | Histological findings | Immunohistoch- e real findings |
|------|---------------------|-----------------------|-----------------------------|
|      | Erythematous and edematous mucosa | Network-pattern erosion in the antrum | Fragile mucosa | Severe inflammatory cell infiltration in the lamina propria | Fibrino-purulent exudate | Epithelaxia | Apoptosis | PD-L1 (%) |
| 1    | +                   | -                     | +                           | +                     | +                 | -              |          | 10 % <   |
| 2    | +                   | +                     | +                           | +                     | -                 | +              | 10 % <   |
| 3    | +                   | -                     | +                           | +                     | -                 | +              |          | 10 % <   |
| 4    | +                   | -                     | +                           | +                     | -                 | +              | 1 %       |

PD-L1, programmed cell death ligand-1; mCPS, modified combined positive score.

| Fig. 1 | Endoscopic features of immune-related adverse event (irAE) gastritis. a The network-pattern erosion and ulcer in the antrum are collectively termed a "spiderweb-like appearance." b Erythematous and edematous mucosa is covered with excessive whitish purulent discharge in the whole stomach. c The fragile mucosa easily bleeds on washing with water spray. d The spiderweb-like appearance is clearly enhanced with narrow-band imaging. | Table 2 | Endoscopic and histological findings and PD-L1 expression in patients with immune-related gastritis. |
air insufflation and mechanical contact during endoscopic examination. Oozing caused by a slight touch was observed in fragile mucosa (Video 1). Narrow-band imaging effectively enhanced erythema as a brownish area, and then contrasted between the mucosa and discharge (Fig. 1d).

Biopsy specimens were collected from the antrum and corpus of the stomach for histological diagnosis. Epithalaxia and severe inflammatory cell infiltration in the epithelia and lamina propria were observed on histology (Fig. 2a). Fibrinopurulent exudate was observed on the epithelia (Fig. 2b). Immunohistochemical analysis showed that the infiltrating lymphocytes were positive for CD3, CD4, and CD8, but negative for CD20 (Supplementary Figure). Staining was positive for PD-L1 in the immune cells and/or epithelial cells (Fig. 2c, d). The positive rate was ≥10% in three cases and ≥1% in one case.

CMV was not detected by a specific antibody in any cases, and H. pylori was detected in the patient with gastric cancer (Case 4).
Treatment and outcome

Treatments for irAE gastritis and the clinical outcomes are shown in ▶Table 1. Corticosteroids (0.5 mg/kg) were administered orally or intravenously. Patient symptoms rapidly improved within a few days of administration. The dose was gradually tapered every 1 to 2 weeks. EGD with a histological examination after treatment with PSL revealed improvement in three cases (▶Fig. 3a–f). In the other case, fragile mucosa remained in the lesser curvature (▶Fig. 3g, h). While the histopathological findings remarkably improved, mild inflammatory cell infiltration persisted in all cases.

In two cases, retreatment with the same ICI was attempted to suppress the regrowing cancer, after the patient’s initial epigastric symptoms had completely resolved. The patient in Case 1 (▶Table 1), who had received nivolumab/ipilimumab, was administered nivolumab monotherapy. The patient in Case 4 was administered nivolumab monotherapy again. Both patients developed loss of appetite and nausea again 10 to 12 weeks after rechallenge with ICIs. EGD revealed relapse of irAE gastritis, characterized by erythematous and edematous mucosa with whitish purulent discharge, and PSL retreatment rapidly improved their symptoms.

Discussion

The number of reported cases of severe irAE gastritis has been increasing in recent years [15–20]. Previously reported cases with severe irAE gastritis are summarized in ▶Table 3. These reports showed that irAE gastritis developed during administration of ICI monotherapy in most cases. Our study included three patients who developed irAE gastritis with ICI monotherapy. Incidence of irAE colitis was shown to be higher in the combination therapy group than in the monotherapy group [21]. In our study, three patients developed irAE gastritis with ICI monotherapy, while one patient developed it with ICI combination therapy. IrAE gastritis seems to develop more frequently with ICI combination therapy, as well as irAE colitis reported in a previous review [22].

To obtain an accurate diagnosis, this study indicates that it is important to be alert for three characteristic endoscopic findings: 1) network-pattern erosion or ulcer in the antrum; 2) erythematous and edematous mucosa with excessive whitish purulent discharge in the whole stomach; and 3) extremely fragile mucosa. Among these findings, the first may be the most specific, and indeed, three of the four patients in our study had this finding. It was unique, enabling it to be distinguished from other etiologies, while the other finding was common findings in gastritis induced by other etiologies. For instance, the second finding can be observed in gastritis caused by severe H. pylori infection [23]. However, the whitish purulent discharge in irAE gastritis was exacerbated by air insufflation and endoscopic contact while performing an endoscopic examination. Furthermore, there were some patients in whom a large amount of whitish purulent discharge covered the mucosal surface, resulting in pseudo-membranous formation. This appearance was described as “fibrin-covered superficial erosions” in a previous report involving endoscopic evaluation of gastrointestinal toxicity [15, 16, 24]. Finally, the third finding was quite characteristic as well. The mucosa of our patients bled easily, even when exposed to the low-pressure water jet from the endoscope. Oozing from mucosa could be observed when the purulent discharge was removed. Endoscopic findings of irAE gastritis in previous reports are summarized in ▶Table 3. Some reports described the endoscopic findings in each pa-
tient, but only a few reports clearly discussed characteristic endoscopic findings of irAE gastritis [14, 25]. Indeed, the first finding was never mentioned in previous reports, aside from our brief case report, in which a white fibrin-like membrane was termed “spiderweb-like appearance” [25].

| Table 3 | Characteristics of 36 cases of ICI-related gastritis in previous reports. |
|---------|----------------------------------------------------------------------------|
| Age     | Median (range) | 63.5 (16–93) |
| Sex     | n               | (Male:female) | 20:16 |
| Type of tumor | n (%)         | Malignant melanoma | 16 (44) |
|          |                | Lung cancer | 10 (28) |
|          |                | Others      | 11 (31) |
| Type of ICI | n (%)       | Pembrolizumab | 14 (39) |
|          |                | Nivolumab | 11 (31) |
|          |                | Ipilimumab + nivolumab | 7 (19) |
|          |                | Ipilimumab | 2 (0.6) |
|          |                | Nivolumab + lag3 inhibitor | 1 (0.3) |
|          |                | Ipilimumab + pembrolizumab | 1 (0.3) |
| Treatment cycles | Median (range) | 2.5 (1–80) |
| Symptoms | n (%) | Abdominal pain (epigastric pain) | 19 (53) |
|          |        | Nausea/vomiting | 14 (39) |
|          |        | Loss of appetite | 11 (31) |
|          |        | Diarrhea | 9 (25) |
|          |        | Weight loss | 4 (1.1) |
|          |        | No symptom | 2 (0.6) |
| Endoscopic findings | n (%) | Erythema | 16 (44) |
|          |        | Erosion/ulcer | 15 (43) |
|          |        | Edematous | 7 (20) |
|          |        | White exudate | 6 (17) |
|          |        | Friable | 8 (23) |
|          |        | Normal | 4 (1.1) |
|          |        | Granularity | 3 (0.9) |
|          |        | Hemorrhagic gastritis | 2 (0.6) |
| Histological findings | n (%) | Inflammatory cell infiltration | 29 (85) |
|          |        | (lymphocytes, neutrophils, eosinophils, plasma cell) |
|          |        | Apoptosis | 10 (29) |
|          |        | Decreased glands | 4 (12) |
| Treatment | n (%) | Prednisolone (0.5–1.0 mg/kg) IV/PO | 31 (89) |
|          |        | Infliximab | 2 (6) |
|          |        | Proton pump inhibitor | 1 (3) |
|          |        | ICI switch | 1 (3) |
|          |        | No treatment | 1 (3) |

ICI, immune checkpoint inhibitor; IV, intravenous; PO, per oral.
The present study compared endoscopic and histopathological findings. The biopsy specimens obtained from the whitish purulent discharge showed fibrinopurulent exudate on the epithelia in our patients. Fibrinopurulent exudate is usually observed in cases of severe gastritis, such as that induced by severe acute *H. pylori* infection, causing extensive infiltration of neutrophils. IrAE gastritis may be more destructive than *H. pylori* gastritis [26]. Presence of fibrinopurulent exudate is considered to reflect the severity of irAE gastritis. Fragile mucosa is consistent with the histological appearance of epithalaxia and gland depletion, which are caused by severe inflammatory cell infiltration and destructive response († Fig. 2a). One of the noteworthy histological findings in gastritis was apoptosis, which is observed in irAE enterocolitis with different frequency [27–29]. Apoptosis is typically observed in gastric graft-versus-host-disease, the histological criteria for which are apoptosis and gland destruction, sparse inflammatory infiltration, and granular eosinophilic debris in the diluted gland. Therefore, the histological distinction will be useful when endoscopic features are similar to irAE gastritis. Differential diagnosis also includes gastric lesions such as in patients with ulcerative colitis. Endoscopic findings of erythematous and edematous mucosa with whitish purulent discharge may be observed in upper gastrointestinal lesions in patients with ulcerative colitis [30,31]. On pathological examination, the lesions show severe inflammation with sloughed epithelial cells, resembling a crypt abscess. Thus, a more detailed histological comparison between ulcerative gastritis and irAE gastritis is expected in the future.

A common mechanism by which ICIs exert their effects involves activation of effector T cells by inhibition of PD-1, PD-L1, and CTLA-4 [32]. It is also proposed that the proliferation of activated T cells and increase in cytokine production, caused by a lack of self-tolerance, may result in irAE gastritis. Differential diagnosis also includes gastrointestinal lesions such as in patients with ulcerative colitis. Endoscopic findings of erythematous and edematous mucosa with whitish purulent discharge may be observed in upper gastrointestinal lesions in patients with ulcerative colitis [30,31]. On pathological examination, the lesions show severe inflammation with sloughed epithelial cells, resembling a crypt abscess. Thus, a more detailed histological comparison between ulcerative gastritis and irAE gastritis is expected in the future.

A common mechanism by which ICIs exert their effects involves activation of effector T cells by inhibition of PD-1, PD-L1, and CTLA-4 [32]. It is also proposed that the proliferation of activated T cells and increase in cytokine production, caused by a lack of self-tolerance, may result in irAE gastritis. Differential diagnosis also includes gastric lesions such as in patients with ulcerative colitis. Endoscopic findings of erythematous and edematous mucosa with whitish purulent discharge may be observed in upper gastrointestinal lesions in patients with ulcerative colitis [30,31]. On pathological examination, the lesions show severe inflammation with sloughed epithelial cells, resembling a crypt abscess. Thus, a more detailed histological comparison between ulcerative gastritis and irAE gastritis is expected in the future.

Concerning the treatment, our patients were treated with intravenous or oral PSL 0.5 mg/kg/day, which rapidly improved their symptoms within a few days to 2 weeks after administration of PSL and the symptoms eventually disappearing. Although the time to symptom improvement was not mentioned much in previous reports, many patients had symptom improvement within a few days of PSL treatment. As with other ir-AEs, there were some PSL-refractory cases that needed an anti-TNFα monoclonal antibody among previous cases [36]. Therefore, we should pay attention to improvement in symptoms after administration of PSL.

One limitation associated with this case report is its retrospective nature and single-center setting. Because gastritis is a relatively rare irAE, we only analyzed endoscopic and histological findings in four collected cases. The sensitivity and specificity of the characteristic endoscopic findings, as mentioned previously, could not be estimated, because the endoscopic findings were not evaluated in this case series. A case-control study or cohort study with a sufficient number of cases would help clarify the accuracy of endoscopic findings.

**Conclusions**

In conclusion, we identified clinical features of irAE gastritis, including characteristic endoscopic findings, in this case series. IrAE gastritis can be induced by any ICI at any timing during administration of ICIs. Furthermore, symptoms of irAE gastritis are non-specific and can resemble those induced by other etiologies, such as disease progression and cachexia. Therefore, it is difficult to diagnose irAE gastritis based on symptoms alone. IrAE gastritis, thus, was diagnosed by characteristic endoscopic findings, and gastritis in patients was effectively treated with PSL. These results suggest that an endoscopic diagnosis is quite important, so oncologists should be aware of characteristic endoscopic findings for this entity. These findings are expected to deepen our understanding of irAE gastritis, leading to prompt diagnosis and appropriate treatment.

**Acknowledgements**

The authors gratefully acknowledge the technical assistance received from Yuji Uno. The authors declare that Case 1 is the same patient who was previously reported in our brief report [ref. 25; Sugiyama Y et al. JGH open 2021].

**Competing interests**

Dr. Okumura has received grant support from Ono Pharmaceutical Corp. and MSD Co., Ltd., and has received payment for honoraria from Ono Pharmaceutical Corporation. Dr. Fujiiya has served as a lecturer for Ono Pharmaceutical Corporation.

**References**

1. Puzanov I, Diab A, Abdallah K. Society for Immunotherapy of Cancer Toxicity Management Working Group. et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017; 5: 95

2. Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med 2018; 378: 158–168
[3] Khoja L, Day D, Wei-Wu Chen T et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol 2017; 28: 2377–2385

[4] Collins M, Michot JM, Danlos FX et al. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Ann Oncol 2017; 28: 2860–2865

[5] Zhang ML, Neyaz A, Patil D et al. Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies. Histopathology 2020; 76: 233–243

[6] Kobayashi M, Yamaguchi O, Nagata K et al. Acute hematogenous gastritis after nivolumab treatment. Gastrointest Endosc 2017; 86: 915–916

[7] Nishimura Y, Yasuda M, Ocho K et al. Severe Gastritis after Administration of Nivolumab and Ipilimumab. Case Rep Oncol 2018; 11: 549–556

[8] Onuki T, Morita E, Sakamoto N et al. Severe upper gastrointestinal disorders in pembrolizumab-treated non-small cell lung cancer patient. Respirology 2018; 23: e1332–e1334

[9] Alhatem A, Patel K, Eriksen B et al. Nivolumab-induced concomitant severe upper and lower gastrointestinal immune-related adverse effects. AGC Case Rep J 2019; 6: e00249

[10] Mahpour NY, Bhagat VH, Sarkar A. Gastritis after combination ipilimumab and nivolumab. Pract Gastroenterol 2019; 43: 40–41

[11] Cheung VTF, Fryer E, Payne MJ et al. Anorexia, vomiting and weight loss in a 22-year-old woman. Gut 2019; 68: 803–927

[12] Calugareanu A, Rompetta P, Boheay G et al. Late onset of nivolumab-induced severe gastroduodenitis and cholangitis in a patient with stage IV melanoma. Immunotherapy 2019; 11: 1005–1013

[13] Woodford R, Briscoe K, Tustin R et al. Immunotherapy-related gastritis: Two case reports and literature review. Clin Med Insights Oncol 2021; 15: doi:10.1177/11795549211028570

[14] Hayashi Y, Hosoe N, Takabayashi K et al. Clinical, endoscopic, and pathological characteristics of immune checkpoint inhibitor-induced Gastroenterocolitis. Dig Dis Sci 2021; 66: 2129–2134

[15] Ebisutani N, Tozawa K, Matsuda I et al. A case of severe acute gastritis as an immune-related adverse event after nivolumab treatment: endoscopic and pathological findings in nivolumab-related gastritis. Dig Dis Sci 2021; 66: 2461–2465

[16] Omothehara S, Nishida M, Yamanashi K et al. A case of immune checkpoint inhibitor-associated gastroenteritis detected by ultrasonography. J Clin Ultrasound 2021; 49: 605–609

[17] Hayama N, Ibara H, Honma Y et al. Severe gastritis due to pembrolizumab treatment in a lung cancer patient. Respirology Case Reports 2020; 8: 1–6

[18] Vindum HH, Agnholt JS, Nielsen AWM et al. Severe steroid refractory gastritis induced by Nivolumab: A case report. World J Gastroenterol 2020; 26: 1971–1978

[19] Rovedatti L, Lenti MV, Vanoli A et al. Nivolumab-associated active neutrophilic gastritis. J Clin Pathol 2020; 73: 605–606

[20] Vangadapelipère J, Siplet J, Libbrecht L et al. Auto-immune gastritis induced by pembrolizumab, an anti-PD-1, in a melanoma patient. Acta Gastroenterol Belg 2020; 83: 482–484

[21] Tran AN, Wang M, Hundt M et al. Immune checkpoint inhibitor-associated diarrhea and colitis: a systematic review and meta-analysis of observational studies. J Immunother 2021; 44: 325–334

[22] Geng Z, Wang Y. Immune checkpoint inhibitor-mediated diarrhea and colitis: a clinical review. JCO Oncol Pract 2020; 16: 453–461

[23] Shah SC, Piazuelo MB, Kuipers EJ et al. AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review. Gastroenterology 2021; 161: 1325–1332

[24] Irazo I, Huguet JM, Suárez P et al. Endoscopic evaluation of immunotherapy-induced gastrointestinal toxicity. World J Gastroenterol 2018; 10: 392–399

[25] Sugiyama Y, Tanabe H, Fujiya M. Immune checkpoint inhibitor-related gastritis in a patient with metastatic melanoma. JGH Open 2021; 5: 1218–1219

[26] Johnellia C, Grover S, Zhang X et al. Morphological spectrum of immune check-point inhibitor therapy-associated gastritis. Histopathology 2020; 76: 531–539

[27] Yanai S, Nakamura S, Kawasaki K et al. Immune checkpoint inhibitor-induced diarrhea: Clinicopathological study of 11 patients. Dig Endosc 2020; 32: 616–620

[28] Abu-Sbeih H, Ali FS, Luo L et al. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer 2018; 6: 95

[29] Dougan M. Checkpoint blockade toxicity and immune homeostasis in the gastrointestinal tract. Front Immunol 2017; 8: 1547

[30] Kato R, Iwamuro M, Hiraoka S et al. Evaluation of the upper gastrointestinal tract in ulcerative colitis patients. Acta Med Okayama 2018; 72: 105–113

[31] Yang Y, Li CQ, Chen WJ et al. Gastroduodenitis associated with ulcerative colitis: A case report. World J Clin Cases 2020; 8: 3847–3852

[32] Chan KK, Bass AR. Autoimmune complications of immunotherapy: pathophysiology and management. BMJ 2020; 369: m736

[33] Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 2018; 359: 1350–1355

[34] van Itzstein MS, Khan S, Gerber DE. Investigational biomarkers for checkpoint inhibitor immune-related adverse event prediction and diagnosis. Clin Chem 2020; 66: 779–793

[35] Johnson DB, McDonnell WJ, Gonzalez-Ericsson PI et al. A case report of clonal EBV-like memory CD4(+) T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nat Med 2019; 25: 1243–1250

[36] Dougan M, Wang Y, Rubio-Tapia A et al. AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review. Gastroenterology 2021; 160: 1384–1393